BACKGROUND: ALZ-801 is an oral, small-molecule inhibitor of beta amyloid (Aβ) oligomer formation in clinical development for Alzheimer's disease (AD). ALZ-801 is a prodrug of tramiprosate with improved pharmacokinetic properties and gastrointestinal tolerability. During clinical studies, we discovered that the primary metabolite of tramiprosate and its prodrug ALZ-801, 3-sulfopropanoic acid (3-SPA), is an endogenous molecule in the human brain and present in the cerebrospinal fluid (CSF) of patients with AD and other neurodegenerative brain diseases. OBJECTIVE: The objectives of this research were to (1) identify and confirm the presence of 3-SPA in CSF samples from elderly, drug-naïve patients with memory deficits; (2) quantify the levels of 3-SPA in the CSF of patients with AD from tramiprosate phase III North American (NA) trial; (3) evaluate the in vitro anti-Aβ42 oligomer activity of 3-SPA; and (4) characterize the pharmacokinetics and brain-penetration properties of 3-SPA. METHODS: Lumbar CSF samples from 64 drug-naïve patients with cognitive deficits (Mini-Mental State Examination [MMSE] score range 15-30) and six patients with AD treated with tramiprosate 150 mg twice daily in the phase III trial, at week 78, were analyzed. We used liquid chromatography-tandem mass spectrometry to confirm the structural molecular identity of endogenous 3-SPA with a 3-SPA reference standard and ion-mobility spectrometry-mass spectrometry with molecular dynamics to characterize interactions of 3-SPA with Aβ42 monomers, and the resultant conformational alterations. Rat studies using oral (30 mg/kg) and intravenous (10 mg/kg) doses were conducted to characterize the pharmacokinetic properties and brain penetration of 3-SPA. RESULTS: We confirmed the presence of 3-SPA in the CSF of drug-naïve patients with cognitive deficits (mean concentration 11.7 ± 4.3 nM). The mean concentration of 3-SPA in patients with AD treated with tramiprosate was 135 ± 51 nM. In vitro studies revealed a multi-ligand interaction of 3-SPA with monomeric Aβ42 that inhibits the aggregation of Aβ42 into small oligomers. Comparisons of the molecular interactions of tramiprosate and 3-SPA with Aβ42 are also presented. Furthermore, in rat preclinical studies, 3-SPA displayed 100% oral bioavailability and 25% brain penetration, indicating that the metabolite is well absorbed and crosses the blood-brain barrier. CONCLUSIONS: We confirmed the endogenous presence of 3-SPA, the major metabolite of tramiprosate, in the CSF of drug-naïve elderly patients with memory deficits due to AD and a variety of other neurodegenerative disorders. The levels of 3-SPA were up to 12.6-fold greater in patients with AD receiving tramiprosate than in drug-naïve patients. In addition, we showed that 3-SPA has potent anti-Aβ oligomer activity, inhibiting aggregation of Aβ42 into small oligomers with efficacy comparable to that of tramiprosate. 3-SPA displays excellent oral availability and brain penetration in rats, suggesting that the higher CSF concentrations of 3-SPA in the human brain after oral administration of ALZ-801 or tramiprosate (and subsequent conversion to 3-SPA) result from the penetration of the metabolite into the central nervous system. These data suggest that 3-SPA is an endogenous agent with potential activity stabilizing the conformational flexibility of Aβ monomers that, in turn, inhibit Aβ misfolding and formation of soluble toxic Aβ oligomers in humans, thereby preventing the initial pathogenic step in the progression of AD. Clinical improvements observed in patients with AD carrying the ε4 allele of the apolipoprotein E gene in tramiprosate phase III studies may in part be explained by the therapeutic effects of excess levels of the metabolite in the brains of these patients. The potential protective role of 3-SPA in AD pathogenesis, as well as its therapeutic role in AD and other neurodegenerative disorders, warrants further investigation.

Alzheon Inc 111 Speen Street Suite 306 Framingham MA 01701 USA

Department of Neurology Cognitive Center 2nd Faculty of Medicine Motol University Hospital Charles University Prague Czech Republic

International Clinical Research Centre St Anne's University Hospital Brno Brno Czech Republic

CNS Drugs. 2018 Dec;32(12):1185. doi: 10.1007/s40263-018-0585-6. PubMed

Zobrazit více v PubMed

Hey JA, Yu Jeremy Y, Versavel M, Abushakra A, Kocis P, Power A, Kaplan PL, Amedio J, Tolar M. Clinical pharmacokinetics and safety of ALZ-801, a novel prodrug of tramiprosate in development for the treatment of Alzheimer’s disease. Clin Pharmacokinet. 2018;57:315–333. doi: 10.1007/s40262-017-0608-3. PubMed DOI PMC

Kocis P, Tolar M, Yu J, Sinko W, Ray S, Blennow K, Fillit H, Hey JA. Elucidating the Abeta42 anti-aggregation mechanism of action of tramiprosate in Alzheimer’s disease: integrating molecular analytical methods. Pharmacokinetic and clinical data. CNS Drugs. 2017;31:495–509. doi: 10.1007/s40263-017-0434-z. PubMed DOI PMC

Abushakra S, Porsteinsson A, Scheltens P, Sadowsky C, Vellas B, Cummings J, Gauthier S, Hey JA, Power A, Wang P, Shen L, Tolar M. Clinical effects of tramiprosate in APOE4/4 homozygous patients with mild Alzheimer’s disease suggest disease modification potential. J Prev Alzheimers Dis. 2017;4:149–156. PubMed

Abushakra S, Porsteinsson A, Vellas B, Cummings J, Gauthier S, Hey JA, Power A, Hendrix S, Wang P, Shen L, Sampalis J, Tolar M. Clinical benefits of tramiprosate in Alzheimer’s disease are associated with higher number of APOE4 alleles: the ‘‘APOE4 gene-dose effect’’. J Prev Alz Dis. 2016;3:219–228. PubMed

Alzheimer’s disease facts and figures. Alzheimer’s Dement 2018;14(3):367–429.

Word Alzheimer Report. London: Alzheimer’s Disease International (ADI); 2016.

Lasser R, Ostrowitz S, Scheltens P, et al. Efficacy and safety of Gantenerumab in prodromal AD: results from Scarlet road—a global, multicenter trial. Alzheimer’s association international conference (AAIC); 2015 (abstract ID 5963).

Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of Bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370:322–333. doi: 10.1056/NEJMoa1304839. PubMed DOI PMC

Sevigny J, Chiao P, Bussiere T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, O’Gorman J, Qian F, Arastu M, Li M, Chollate S, Brennan MS, Quintero-Monzon O, Scannevin RH, Arnold HM, Engber T, Rhodes K, Ferrero J, Hang Y, Mikulskis A, Grimm J, Hock C, Nitsch RM, Sandrock A. The antibody aducanumab reduces Abeta plaques in Alzheimer’s disease. Nature. 2016;537:50–56. doi: 10.1038/nature19323. PubMed DOI

Viglietta V, O’Gorman J, Williams L, Chen T, Enayetallah A, Chiao P, Hock C, Nitsch RM, Haeberlein AB, Sandrock A. Aducanumab titration dosing regimen: 12-month interim analysis from prime, a randomized double blind, placebo controlled phase Ib study in patients with prodromal or mild Alzheimer’s disease. J Prev Alzheimers Dis. 2016;3(suppl 1):378.

Caselli RJ, Dueck AC, Osborne D, et al. Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. N Engl J Med. 2009;361:255–263. doi: 10.1056/NEJMoa0809437. PubMed DOI PMC

Esparza TJ, Zhao H, Cirrito JR, Cairns NJ, Bateman RJ, Holtzman DM, Brody DL. Amyolid beta oligomerization in Alzheimer’s dementia vs. high pathology controls. Ann Neurol. 2013;73(1):104–119. doi: 10.1002/ana.23748. PubMed DOI PMC

Viola KL, Klein WL. Amyloid β oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis. Acta Neuropathol. 2015;129:183–206. doi: 10.1007/s00401-015-1386-3. PubMed DOI PMC

Usui K, Hulleman JD, Paulsson JF, Siegel SJ, Powers ET, Kelly JW. Site-specific modification of Alzheimer’s peptides by cholesterol oxidation products enhances aggregation energetics and neurotoxicity. PNAS. 2009;106:18563–18568. doi: 10.1073/pnas.0804758106. PubMed DOI PMC

Hashimoto T, Serrano-Pozo A, Hori Y, et al. Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid β peptide. J Neurosci. 2012;32:15181–15192. doi: 10.1523/JNEUROSCI.1542-12.2012. PubMed DOI PMC

Ono K, Yamada M. Low-n oligomers as therapeutic targets of Alzheimer’s disease. J Neurochem. 2011;117:19–28. doi: 10.1111/j.1471-4159.2011.07187.x. PubMed DOI

Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ. Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol. 2006;572:477–492. doi: 10.1113/jphysiol.2005.103754. PubMed DOI PMC

Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, et al. Diffusible, nonfibrillar ligands derived from A 1–42 are potent central nervous system neurotoxins. PNAS. 1998;95:6448–6453. doi: 10.1073/pnas.95.11.6448. PubMed DOI PMC

Jin M, Selkoe DJ. Systematic time analysis of time-dependent neural effects of soluble amyloid oligomers in culture and in vivo: prevention by scyllo-inositol. Neurobiol Dis. 2015;82:152–163. doi: 10.1016/j.nbd.2015.05.020. PubMed DOI PMC

Vanderstichele H, Bibl M, Engelborghs S, et al. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer’s disease diagnosis: a consensus paper from the Alzheimer’s biomarkers standardization initiative. Alzheimers Dement. 2012;8(1):65–73. doi: 10.1016/j.jalz.2011.07.004. PubMed DOI

Hort J, Glosova L, Vyhnalek M, Bojar M, Skoda D, Hladikova M. The liquor tau protein and beta amyloid in Alzheimer’s disease. Cesk Slov Neurol N. 2007;70(1):30–36.

Shivakumar D, Harder E, Damm W, Friesner RA, Sherman W. Improving the prediction of absolute solvation free energies using the next generation OPLS force field. J Chem Theory Comput. 2012;8:2553–2558. doi: 10.1021/ct300203w. PubMed DOI

Bakan A, Meireles LM, Bahar I. ProDy: protein dynamics inferred from theory and experiments. Bioinformatics. 2011;27:1575–1577. doi: 10.1093/bioinformatics/btr168. PubMed DOI PMC

Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al. Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Ann Neurol. 2009;65:403–413. doi: 10.1002/ana.21610. PubMed DOI PMC

Pannee J, Portelius E, Minthon L, Gobom J, Andreasson U, Zetterberg H, et al. Reference measurement procedure for CSF Abeta1-42 and the CSF Abeta1-42 /Abeta1-40 ratio—a crossvalidation study against amyloid PET. J Neurochem. 2016;139:651–658. doi: 10.1111/jnc.13838. PubMed DOI

Herukka S-K, Rummukainen J, Ihalainen J, Und Zu Fraunberg von M, Koivisto AM, Nerg O, et al. Amyloid-beta and tau dynamics in human brain interstitial fluid in patients with suspected normal pressure hydrocephalus. J Alzheimers Dis. 2015;46:261–269. doi: 10.3233/JAD-142862. PubMed DOI

Lue L-F, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer’s disease. Am J Pathol. 1999;155:853–862. doi: 10.1016/S0002-9440(10)65184-X. PubMed DOI PMC

Gervais F, Paquette J, Morissette C, Krzywkowski P, Yu M, Azzi M, et al. Targeting soluble Aβ peptide with tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging. 2007;28:537–547. doi: 10.1016/j.neurobiolaging.2006.02.015. PubMed DOI

Sinha S, Lopes DHJ, Bitan G. A key role for lysine residues in amyloid β-protein folding, assembly, and toxicity. ACS Chem Neurosci. 2012;3:473–481. doi: 10.1021/cn3000247. PubMed DOI PMC

Lehninger AL. Lehninger principles of biochemistry. 4. New York: W.H Freeman; 2005.

Zhang Tong, Creek Darren J, Barrett Michael P, Blackburn Gavin, Watson David G. Evaluation of coupling reversed phase. Aqueous normal phase, and hydrophilic interaction liquid chromatography with Orbitrap mass spectrometry for metabolomic studies of human urine analytical chemistry. Anal Chem. 2012;84:1994–2001. doi: 10.1021/ac2030738. PubMed DOI

Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer's Disease

CoVAMPnet: Comparative Markov State Analysis for Studying Effects of Drug Candidates on Disordered Biomolecules

Domino-like effect of C112R mutation on ApoE4 aggregation and its reduction by Alzheimer's Disease drug candidate